JIANGSU RECBIO TECHNOLOGY CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.97 CNY | -0.22% |
|
-2.18% | -17.40% |
| 06-18 | Jiangsu Recbio Technology Co., Ltd. Announces Change of Joint Company Secretary | CI |
| 05-08 | Jiangsu Recbio Technology Co., Ltd. Approves Election of Wang Ruwei as A Non-Executive Director | CI |
Valuation
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Capitalization 1 | 10,493 | 4,741 | 4,000 | - | - |
| Enterprise Value (EV) 1 | 9,450 | 4,557 | 4,579 | 5,092 | 5,041 |
| P/E ratio | -14.3 x | -8.29 x | -7.84 x | -8.31 x | -33.4 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | 14.1 x |
| EV / Revenue | - | - | - | - | 17.8 x |
| EV / EBITDA | -13.7 x | -9.12 x | -10.6 x | -13.1 x | -231 x |
| EV / FCF | -10,784,864 x | - | - | - | - |
| FCF Yield | -0% | - | - | - | - |
| Price to Book | 6.31 x | 4.43 x | 8.03 x | 55.7 x | -83.5 x |
| Nbr of stocks (in thousands) | 482,963 | 480,319 | 479,152 | - | - |
| Reference price 2 | 21.73 | 9.871 | 8.348 | 8.348 | 8.348 |
| Announcement Date | 20/03/23 | 20/03/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | 283.6 |
| EBITDA 1 | - | -691.2 | -499.4 | -430.3 | -387.3 | -21.85 |
| EBIT 1 | - | -732.5 | -659.4 | -527.9 | -488.7 | -123.5 |
| Operating Margin | - | - | - | - | - | -43.54% |
| Earnings before Tax (EBT) 1 | - | -736 | -572.4 | -516.9 | -486.8 | -121.7 |
| Net income 1 | -657.6 | -722.7 | -572 | -516.6 | -486.5 | -121.5 |
| Net margin | - | - | - | - | - | -42.84% |
| EPS 2 | -1.560 | -1.520 | -1.190 | -1.065 | -1.005 | -0.2500 |
| Free Cash Flow | - | -876.3 | - | - | - | - |
| FCF margin | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - |
| Announcement Date | 20/03/22 | 20/03/23 | 20/03/24 | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | 579 | 1,092 | 1,041 |
| Net Cash position 1 | - | 1,043 | 184 | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | -1.345 x | -2.82 x | -47.63 x |
| Free Cash Flow | - | -876 | - | - | - | - |
| ROE (net income / shareholders' equity) | - | -43.3% | -42% | -73.9% | -332% | - |
| ROA (Net income/ Total Assets) | - | -34.2% | - | -29.5% | -20.4% | -12.5% |
| Assets 1 | - | 2,114 | - | 1,751 | 2,385 | 971.9 |
| Book Value Per Share 2 | - | 3.440 | 2.230 | 1.040 | 0.1500 | -0.1000 |
| Cash Flow per Share | - | - | - | - | - | - |
| Capex 1 | - | 297 | - | 150 | 122 | 100 |
| Capex / Sales | - | - | - | - | - | 35.26% |
| Announcement Date | 20/03/22 | 20/03/23 | 20/03/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
8.348
CNY
Average target price
11.99
CNY
Spread / Average Target
+43.59%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -17.40% | 550M | |
| +2.99% | 95.18B | |
| -4.34% | 37.55B | |
| -10.41% | 33.75B | |
| +75.79% | 28.2B | |
| -14.61% | 15.63B | |
| -3.46% | 13.63B | |
| -12.31% | 11.5B | |
| +184.77% | 10.81B | |
| -54.13% | 9.23B |
- Stock Market
- Equities
- 2179 Stock
- Financials Jiangsu Recbio Technology Co., Ltd.
